Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer

Leonard B. Saltz, John V. Cox, Charles Blanke, Lee S. Rosen, Louis Fehrenbacher, Malcolm J. Moore, Jean A. Maroun, Stephen P. Ackland, Paula K. Locker, Nicoletta Pirotta, Gary L. Elfring, Langdon L. Miller

Research output: Contribution to journalArticle

2703 Citations (Scopus)

Abstract

Background: The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone. Methods: Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival. Results: Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P=0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life. Conclusions: Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival. (C) 2000, Massachusetts Medical Society.

Original languageEnglish (US)
Pages (from-to)905-914
Number of pages10
JournalNew England Journal of Medicine
Volume343
Issue number13
DOIs
StatePublished - Sep 28 2000

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Disease-Free Survival
Therapeutics
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., ... Miller, L. L. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 343(13), 905-914. https://doi.org/10.1056/NEJM200009283431302

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. / Saltz, Leonard B.; Cox, John V.; Blanke, Charles; Rosen, Lee S.; Fehrenbacher, Louis; Moore, Malcolm J.; Maroun, Jean A.; Ackland, Stephen P.; Locker, Paula K.; Pirotta, Nicoletta; Elfring, Gary L.; Miller, Langdon L.

In: New England Journal of Medicine, Vol. 343, No. 13, 28.09.2000, p. 905-914.

Research output: Contribution to journalArticle

Saltz, LB, Cox, JV, Blanke, C, Rosen, LS, Fehrenbacher, L, Moore, MJ, Maroun, JA, Ackland, SP, Locker, PK, Pirotta, N, Elfring, GL & Miller, LL 2000, 'Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer', New England Journal of Medicine, vol. 343, no. 13, pp. 905-914. https://doi.org/10.1056/NEJM200009283431302
Saltz, Leonard B. ; Cox, John V. ; Blanke, Charles ; Rosen, Lee S. ; Fehrenbacher, Louis ; Moore, Malcolm J. ; Maroun, Jean A. ; Ackland, Stephen P. ; Locker, Paula K. ; Pirotta, Nicoletta ; Elfring, Gary L. ; Miller, Langdon L. / Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. In: New England Journal of Medicine. 2000 ; Vol. 343, No. 13. pp. 905-914.
@article{144d466871384d5c8d686ddf80c0897f,
title = "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer",
abstract = "Background: The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone. Methods: Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival. Results: Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P=0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life. Conclusions: Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival. (C) 2000, Massachusetts Medical Society.",
author = "Saltz, {Leonard B.} and Cox, {John V.} and Charles Blanke and Rosen, {Lee S.} and Louis Fehrenbacher and Moore, {Malcolm J.} and Maroun, {Jean A.} and Ackland, {Stephen P.} and Locker, {Paula K.} and Nicoletta Pirotta and Elfring, {Gary L.} and Miller, {Langdon L.}",
year = "2000",
month = "9",
day = "28",
doi = "10.1056/NEJM200009283431302",
language = "English (US)",
volume = "343",
pages = "905--914",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

TY - JOUR

T1 - Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer

AU - Saltz, Leonard B.

AU - Cox, John V.

AU - Blanke, Charles

AU - Rosen, Lee S.

AU - Fehrenbacher, Louis

AU - Moore, Malcolm J.

AU - Maroun, Jean A.

AU - Ackland, Stephen P.

AU - Locker, Paula K.

AU - Pirotta, Nicoletta

AU - Elfring, Gary L.

AU - Miller, Langdon L.

PY - 2000/9/28

Y1 - 2000/9/28

N2 - Background: The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone. Methods: Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival. Results: Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P=0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life. Conclusions: Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival. (C) 2000, Massachusetts Medical Society.

AB - Background: The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone. Methods: Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival. Results: Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P=0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life. Conclusions: Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival. (C) 2000, Massachusetts Medical Society.

UR - http://www.scopus.com/inward/record.url?scp=0034727063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034727063&partnerID=8YFLogxK

U2 - 10.1056/NEJM200009283431302

DO - 10.1056/NEJM200009283431302

M3 - Article

VL - 343

SP - 905

EP - 914

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -